Get the Stockscreener App
7.99
0.37%
-0.03
After Hours:
7.99
Amicus Therapeutics Inc stock is traded at $7.99, with a volume of 2.88M.
It is down -0.37% in the last 24 hours and up +14.47% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$8.02
Open:
$8
24h Volume:
2.88M
Relative Volume:
0.65
Market Cap:
$2.46B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-23.50
EPS:
-0.34
Net Cash Flow:
$-31.51M
1W Performance:
+0.00%
1M Performance:
+14.47%
6M Performance:
-10.12%
1Y Performance:
-29.17%
1-Day Range:
$7.92
$8.11
1-Week Range:
$7.785
$8.19
52-Week Range:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
7.99 | 2.45B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Comerica Bank Decreases Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Parkman Healthcare Partners LLC Reduces Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Cubist Systematic Strategies LLC Invests $4.51 Million in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Trexquant Investment LP Sells 715,377 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
166,491 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Banque Transatlantique SA - MarketBeat
Amicus Therapeutics Presents Long-Term Efficacy Data for Cipaglucosidase Alfa and Miglustat in Late-Onset Pompe Disease at ICIEM 2025 - Quiver Quantitative
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM - GlobeNewswire
Breakthrough 4-Year Results: Amicus Pompe Disease Treatment Maintains Muscle Function in Long-term Study - Stock Titan
Vestal Point Capital LP Grows Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Dark Forest Capital Management LP Raises Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Palo Alto Investors LP Sells 317,477 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
683 Capital Management LLC Acquires New Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. $FOLD is Redmile Group LLC's 3rd Largest Position - MarketBeat
PDT Partners LLC Buys 388,817 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Rafferty Asset Management LLC Trims Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Can Amicus Therapeutics Inc. outperform under higher oil pricesPrice Action & Expert-Curated Trade Recommendations - خودرو بانک
Ranking Amicus Therapeutics Inc. among high performing stocks via toolsWeekly Investment Recap & Advanced Technical Signal Analysis - Newser
What analysts say about Amicus Therapeutics Inc. stockWeekly Profit Recap & Verified Chart Pattern Trade Signals - خودرو بانک
Is Amicus Therapeutics Inc. a candidate for recovery playPortfolio Return Summary & AI Driven Stock Reports - Newser
Can a trend reversal in Amicus Therapeutics Inc. lead to recoveryJuly 2025 Update & Safe Capital Allocation Plans - Newser
Amicus Therapeutics Inc. stock momentum explained2025 Market Sentiment & Growth Focused Investment Plans - Newser
How to read the order book for Amicus Therapeutics Inc.2025 Stock Rankings & Daily Market Momentum Tracking - Newser
Is this a good reentry point in Amicus Therapeutics Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - Newser
Using economic indicators to assess Amicus Therapeutics Inc. potentialJuly 2025 Recap & Pattern Based Trade Signal System - Newser
Evaluating Amicus Therapeutics Inc. with trendline analysisMarket Performance Recap & Reliable Price Breakout Alerts - Newser
Is Amicus Therapeutics Inc. reversing from oversold territory2025 Macro Impact & Verified Momentum Watchlists - Newser
Quantitative breakdown of Amicus Therapeutics Inc. recent moveMarket Rally & Scalable Portfolio Growth Methods - Newser
Kodai Capital Management LP Purchases New Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Using AI based signals to follow Amicus Therapeutics Inc.Portfolio Performance Report & AI Forecasted Entry/Exit Points - Newser
Wall Street Zen Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold - MarketBeat
Should you hold or exit Amicus Therapeutics Inc. now2025 Volatility Report & Short-Term Trading Alerts - Newser
Russell Investments Group Ltd. Increases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Real time social sentiment graph for Amicus Therapeutics Inc.2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Reversal indicators forming on Amicus Therapeutics Inc. stockJuly 2025 Drop Watch & Reliable Price Breakout Alerts - Newser
Using Python tools to backtest Amicus Therapeutics Inc. strategiesCEO Change & Reliable Price Action Trade Plans - Newser
Earnings visualization tools for Amicus Therapeutics Inc.2025 AllTime Highs & Verified Short-Term Plans - Newser
How to build a custom watchlist for Amicus Therapeutics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser
Applying Wyckoff theory to Amicus Therapeutics Inc. stockJuly 2025 Levels & Safe Capital Investment Plans - Newser
Is Amicus Therapeutics Inc. stock a buy or sell getLinesFromResByArray error: size == 0 - 머스트 뉴스
Has Amicus Therapeutics Inc. found a price floorMarket Risk Analysis & Low Risk High Reward Trade Ideas - Newser
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):